Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indacaterol xinafoate
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
**Indacaterol xinafoate** is a salt form of indacaterol, a long-acting beta-2 adrenergic receptor agonist (LABA) developed for inhalation therapy. It acts as a bronchodilator by selectively stimulating beta-2 adrenergic receptors in airway smooth muscle, resulting in muscle relaxation and improved airflow. Indacaterol xinafoate has been studied as a potential alternative to other indacaterol salt forms (e.g., maleate, acetate) for the treatment of asthma and respiratory diseases. It was originally developed by Novartis and has been investigated in clinical trials for asthma[3][5].
- Other names
- indacaterol xinafoate
02
Targets
ADRB2 (β2)
Beyond the preview
Go deeper on indacaterol xinafoate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indacaterol xinafoate.